Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 13/20 | 0.49 |
| ▸ | DPP7 | Q9UHL4 | 7/20 | 0.49 |
| ▸ | FAP | Q12884 | 6/20 | 0.49 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.42 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.39 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14186209 | 0.98 | DPP4 (0.48) | DPP4DPP7FAPDPP8DPP9 | |
| SCHEMBL14186213 | 0.95 | DPP4 (0.48) | DPP4DPP7FAPDPP8DPP9 | |
| SCHEMBL24260361 | 0.94 | DPP4 (0.43) | DPP4DPP7FAPDPP8DPP9 | |
| SCHEMBL14186210 | 0.93 | DPP4 (0.46) | DPP4DPP7FAPPOLBL3MBTL1 | |
| SCHEMBL24260140 | 0.92 | DPP4 (0.42) | DPP4DPP7FAPKMT2AHRH3 | |
| SCHEMBL24260493 | 0.86 | CHRM2 (0.38) | DPP4DPP7FAPEPHX2EPHX1 | |
| SCHEMBL24260117 | 0.86 | HRH3 (0.39) | DPP4DPP7FAPKMT2AHRH3 | |
| SCHEMBL24260121 | 0.85 | KDM4E (0.38) | DPP4DPP7FAPKMT2ACHRM2 | |
| SCHEMBL24260147 | 0.85 | DPP4 (0.40) | DPP4DPP7FAPDPP8DPP9 | |
| SCHEMBL14186214 | 0.84 | DPP4 (0.42) | DPP4DPP7FAPDPP8DPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080119515-A1 | Heterocyclic Kinase Inhibitors: Methods of Use and Synthesis | SCHERING CORPORATION | 2008-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119515-A1 | Heterocyclic Kinase Inhibitors: Methods of Use and Synthesis | MAP3K20, MAP3K1, MAP3K19 | DPP4 2848/4885DPP7 2075/4885FAP 2178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.